The study is designed to clarify the clinical characteristics, risk factors and long-term prognosis of children with 2019-nCoV infection in China.
As of February 10th, 2020, more than 40,000 human have been confirmed infected with a novel coronavirus (2019-nCoV) in China, with at least 800 reported deaths. Additional cases have been confirmed in multiple countries, and some are reported in children. Patients with confirmed 2019-nCoV infection have reported respiratory illness with fever, cough, et al. Some are asymptomatic carriers. However, there are relatively few diagnosed cases of children, and the long-term prognosis is unknown. Therefore, a multicenter observational study is needed to better understand the clinical characteristics of 2019-nCoV infection in children. This observational study will last from February to December 2020. The patients enrolled were diagnosed with 2019-nCoV infection or 2019-nCoV pneumonia by Beijing Children's Hospital and other members of Chinese National Clinical Research Center for Respiratory Diseases in 2019-2020. At the same time, children hospitalized with pneumonia other than 2019-nCoV pneumonia during the same period are classified as the control group by 3\~5:1 matching for age and sex to the 2019-nCoV group. After guardians signing the informed consent forms, all the participants' clinical data, laboratory examination results, image data and also the follow-up information after six months of their treatment will be collected. The trial will be completed in 10 months, with subjects recruited from the hospitals that in partnership with clinical research collaboration of National Clinical Research Center for Respiratory Diseases.
Study Type
OBSERVATIONAL
Enrollment
500
Beijing Children's Hospital,
Beijing, China
The cure rate of 2019-nCoV.
Percentage
Time frame: 6 months
The improvement rate of 2019-nCoV.
Percentage
Time frame: 6 months
The incidence of long-term adverse outcomes.
Time frame: 6 months
Duration of fever
Days
Time frame: 2 weeks
Duration of respiratory symptoms
Days
Time frame: 2 weeks
Duration of hospitalization
Days
Time frame: 2 weeks
Number of participant(s) need intensive care
Time frame: 2 weeks
Number of participant(s) with acute respiratory distress syndrome
Time frame: 2 weeks
Number of participant(s) with extra-pulmonary complications, including shock, renal failure, multiple organ failure, hemophagocytosis syndrome, et al.
Time frame: 2 weeks
Number of participant(s) who died during the trial
Time frame: 10 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.